Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

NEW YORK – The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as a treatment for patients with ...

[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

During treatment with aromatase inhibitor letrozole, assessment of liver function, lipids, hemoglobin and hematocrit were performed every 6-12 months. Hormonal analysis was performed at each ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

Video content above is prompted by the following: The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy ...